drugset
drugset / Trial / NCT07601334

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

NCT07601334 ↗

Phase 1 Not yet recruiting 45 enrolled HighField Biopharmaceuticals Corporation
NaSingle-groupOpen-labelTreatment

Summary

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Timeline

Start
2026-06-30
Primary completion
2028-06-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HF50 Other / unclassified — Intravenous

Indications

cancer